当前位置: X-MOL 学术Obstet. Gynecol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G Levels After the Pfizer-BioNTech Booster Dose for Coronavirus Disease 2019 (COVID-19) Vaccination During the Second Trimester of Pregnancy
Obstetrics and Gynecology ( IF 7.2 ) Pub Date : 2022-08-01 , DOI: 10.1097/aog.0000000000004867
Nir Kugelman 1 , Chen Nahshon , Pninit Shaked-Mishan , Shiran Kleifeld , Nadav Cohen , Maayan Lahav Sher , Hazar Zahran , Hanin Barsha , Wisam Assaf , Eiman Shalabna , Nili Stein , Ofer Lavie , Reuven Kedar , Shlomit Riskin-Mashiah
Affiliation  

OBJECTIVE: 

To evaluate maternal and neonatal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) antibody levels at birth after a third (booster) dose of the Pfizer-BioNTech messenger RNA (Pfizer) coronavirus disease 2019 (COVID-19) vaccine during the second trimester of pregnancy, and compare them with those in women who received two vaccine doses during the second trimester.

METHODS: 

We conducted a prospective cohort study of women admitted to the delivery ward at a single center who received the third Pfizer COVID-19 vaccine dose (booster group) at 17–30 weeks of pregnancy and who did not have previous SARS-CoV-2 infection. Maternal and neonatal antibody levels were measured on admission for delivery and in the umbilical cord blood after birth. Antibody levels for the booster group were compared with those in a historical control group of pregnant women who received their second vaccine dose (two-dose group) within the same gestational age window.

RESULTS: 

Between October 2021 and February 2022, antibody levels were measured in 121 women and 109 neonates at a mean±SD of 15.3±3.9 weeks after booster vaccination. Neonatal titers measured two times higher than maternal titers, with inverse correlation between maternal and neonatal titers at birth and time interval from third vaccination. The two-dose group included 121 women and 107 neonates, with antibody levels measured at a mean±SD of 14.6±2.6 weeks after the second dose. Median [interquartile range] maternal antibody titers were higher in the booster group (4,485 [2,569–9,702] AU/mL) compared with the two-dose group (1,122 [735–1,872] AU/mL) (P<.001). Furthermore, neonatal antibody titers were higher in the booster group (8,773 [5,143–18,830] AU/mL) compared with the two-dose group (3,280 [2,087–5,754] AU/mL) (P<.001).

CONCLUSION: 

Maternal and neonatal SARS-CoV-2 IgG antibody titers after second-trimester maternal Pfizer COVID-19 vaccination were significantly higher after the booster dose compared with the two-dose vaccination series. Although there is uncertainty as to whether antibody levels correlate with protection, these data support the importance of booster vaccination during pregnancy to restore maternal and neonatal protection against COVID-19.



中文翻译:

孕中期接种辉瑞-BioNTech 2019 冠状病毒病 (COVID-19) 疫苗后的母婴严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 免疫球蛋白 G 水平

客观的: 

评估孕产妇和新生儿严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 免疫球蛋白 G (IgG) 抗体水平在第三剂辉瑞-BioNTech 信使 RNA (Pfizer) 2019 冠状病毒病 (COVID- 19) 在妊娠中期接种疫苗,并将其与在妊娠中期接种两次疫苗的妇女进行比较。

方法: 

我们对单中心分娩病房的女性进行了一项前瞻性队列研究,这些女性在怀孕 17-30 周时接种了第三剂辉瑞 COVID-19 疫苗(加强组),并且之前没有感染过 SARS-CoV-2 . 在分娩时和出生后的脐带血中测量母体和新生儿的抗体水平。将加强组的抗体水平与在同一胎龄窗口内接种第二剂疫苗的孕妇的历史对照组(两剂组)的抗体水平进行比较。

结果: 

在 2021 年 10 月至 2022 年 2 月期间,在加强疫苗接种后 15.3±3.9 周的平均±标准差为 121 名妇女和 109 名新生儿测量了抗体水平。新生儿滴度测量值是母体滴度的两倍,出生时母体和新生儿滴度与第三次疫苗接种的时间间隔呈负相关。两剂组包括 121 名妇女和 107 名新生儿,抗体水平在第二剂后 14.6±2.6 周测量的平均值±标准差。与两剂组(1,122 [735-1,872] AU/mL)相比,加强组的母源抗体滴度中位数(4,485 [2,569–9,702] AU/mL)更高(P <.001)。此外,与两次剂量组(3,280 [2,087-5,754] AU/mL)相比,加强组的新生儿抗体滴度(8,773 [5,143–18,830] AU/mL)更高(P <.001)。

结论: 

与两剂疫苗系列相比,加强剂量后孕中期孕产妇辉瑞 COVID-19 疫苗接种后的孕产妇和新生儿 SARS-CoV-2 IgG 抗体滴度显着更高。尽管抗体水平是否与保护相关尚不确定,但这些数据支持在怀孕期间加强疫苗接种以恢复母婴对 COVID-19 的保护的重要性。

更新日期:2022-07-22
down
wechat
bug